Surabaya, KOMPAS.com
Avian Influenza Research Centre Bio Safety Level-3 the Airlangga University, Surabaya, East Java, launched the future vaccine H1N1 and H5N1, on Monday (16/11) in Surabaya. The vaccine H1N1 will begin to be produced in November 2010 by PT Bio Farma. In the launching agenda, the Rector Unair Prof Fasich handed over the future vaccine (seed vaccine) H1N1 and H5N1 to Vice President Boediono, that handed over him to Health Minister Endang Rahayu Sedyaningsih and continued to the Managing Director PT Bio Farma, Iskandar. According to Iskandar, the future vaccine H1N1 will be tested clinical (clinical trial) to humankind in March 2010. The production and the distribution of the vaccine H1N1 was carried out in November 2010 for 20 million doses of the vaccine or a tenth of the inhabitants’s Indonesian number. Because of the number of limited productions, said Endang, the vaccine was given priority to the community’s group that was susceptible to avian influenza (AI), like the nurse and the official of the laboratory.
The vaccine H5N1 will be produced in accordance with the policy of the government. If the pandemic happening and the government asked for the production of the vaccine H5N1, PT Bio Farma will produce because of technology for the production of the two vaccines are same.
The head of the Avian Influenza Tropical Disease Center Laboratory (TDC) Unair Chairul Anwar Nidom explained, if the mutation of the virus happening in H1N1 or H5N1, strain the virus that was used as the future vaccine will be replaced. ”Information on the infection incident avian influenza are really needed,” Nidom words.
Iskandar said, thought the development project of the laboratory and production facilities of the vaccine H1N1 and H5N1 in the C Unair Campus, Mulyorejo, Surabaya, around Rp 1.3 trillion. Production facilities had a capacity of 20 million vaccines per year. The project was carried out four years, 2008-2011. Nidom added, the virus research of H5N1 to be made vaccine has been carried out since 2006. For the test about (the testing of the prospective vaccine to the animal) H5N1 was waiting for the sample of the virus from the Department of the Health to August 13 2009. At that time TDC Unair received six types of the virus H5N1. The research H1N1 was easier because of TDC Unair to be able to get many samples of the virus from the clinic. After being tested, the future vaccine was ready to be tested clinical and began to be produced mass.
The AI virus research and it future vaccine were carried out in the laboratory measuring 224 square metres had a name Avian Influenza Research Centre Bio Safety Level-3 (BSL-3). It was the biggest in Asia, said Nidom, this laboratory was unique because of having test space to 30 monkeys (Maccaca fascicularis). The research in the laboratory was very comprehensive. The launching of this future vaccine, according to Boediono, was the shape of Indonesian autonomy. As citizens of the world, Indonesia must active handled the very fast infectious diseases attack spread. Moreover, as the tropical country, Indonesia was very susceptible as the multiplying place strain and the mutation of the new virus. Because in the warfare front line opposed infectious diseases, he continued, Indonesia had the opportunity to control its technology. Therefore, Indonesia better not make themselves dependent to the laboratory overseas. ”Indonesia also had an obligation to divide knowledge to the world because the plague of infectious diseases was the problem of the world, but in the framework mutually benefitable” he said.
Researcher activities in Avian Influenza Research Centre BSL-3 of Airlangga University, Surabaya, East Java, which was launched by Vice President of Indonesia Boediono, Monday (16/11). In this event was also launched the vaccine candidate (seed vaccine) H1N1 and H5N1. For the beginning stage of the vaccine H1N1 will be produced by Bio Farma.
More info :
http://kesehatan.kompas.com/read/xml/2009/11/17/0733293/vaksin.h1n1.diproduksi.tahun.depan










